SX-682 is moving into a new clinical context. After an ongoing trial in prostate cancer with androgen receptor pathway inhibitors such as apalutamide and enzalutamide, the CXCR1/2 inhibitor is now being studied with docetaxel in recurrent/metastatic head and neck squamous cell carcinoma, salivary gland carcinoma, and advanced prostate cancer. That matters because docetaxel is not […]
177Lu‑PSMA‑VG01 is a next‑generation, small‑molecule PSMA‑targeting radiopharmaceutical designed to refine what 177Lu‑PSMA‑617 (Pluvicto) has already achieved. It uses a high‑affinity ligand to deliver the beta‑emitter lutetium‑177 directly to PSMA‑expressing tumor cells, aiming for greater tumor dosing with less exposure of healthy tissue. A new phase 1 trial is testing its dosimetry and side effects on […]
MVB-101 (aka CBP-1018) is a new clinical-stage drug conjugate for prostate cancer simultaneously targets PSMA and folate receptor alpha (FRα) to overcome tumor heterogeneity. The drug is a bivalent peptide-like drug conjugate roughly one-fiftieth the size of a traditional antibody drug conjugate, designed to diffuse more rapidly into solid tumors. It delivers monomethyl auristatin E […]
The RIALTO trial challenges decades of oncology dogma that treating the prostate becomes irrelevant once cancer spreads. For patients with de novo metastasized prostate cancer who show incomplete PSA-response (PSA >0.2 ng/ml after six months of combined ADT+ARPI), the prostate may function as a persistent tumor reservoir continuously seeding metastases. Local radiotherapy to the prostate […]
61Cu-NU101 is a new PSMA-targeted PET/SPECT tracer for prostate cancer that showed promise in phase 1, detecting more lesions than 18F-piflufolastat (Pylarify) in half of the 8 patients studied, with lower background uptake and no side effects. The key advantage is its 3.3-hour half-life, compared to 68 minutes for 68Ga-PSMA-11 and 109 minutes for 18F-piflufolastat. […]
Prostate cancer can become harder to treat when it changes from the usual adenocarcinoma form into neuroendocrine prostate cancer, or NEPC. A recent study suggests that this transition may begin earlier than expected, during an intermediate phase when the cells are still partly prostate-like but are already starting to acquire neuroendocrine features. A central finding […]
Rucaparib continues to strengthen its position in BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), an advanced form of prostate cancer that progresses despite hormonal therapy, with TRITON3 trial confirming not only its efficacy but also a predictable and manageable safety profile. In this phase 3 study of chemotherapy-naïve patients progressing after one prior androgen receptor pathway […]
A first-in-human imaging trial of DOTA-STR-17126 just started in Australia. It is an open-label, single-arm early phase 1 study enrolling up to 20 adults with advanced or metastatic prostate or breast cancer who have exhausted standard treatments. The trial uses a theranostic approach. Participants receive gallium-68 DOTA-STR-17126 for PET imaging to detect tumors expressing the […]
GV20-0251 is an experimental antibody that blocks a new immune brake called IGSF8, and this phase 2 study tests it together with anti-PD-1 drugs in people with advanced solid tumors that no longer respond to standard treatment. The goal is to restore early innate immune signaling so checkpoint therapy works better in resistant cancers. From […]
Zanzalintinib is being tested after Pluvicto (177Lu-PSMA-617) in metastatic castration‑resistant prostate cancer (mCRPC) because it targets several escape routes tumors use once they have survived PSMA‑directed radioligand therapy and prolonged AR pathway blockade. Pluvicto delivers beta radiation to PSMA‑expressing cells, inducing DNA damage and tumor cell death, but progression still occurs and is often driven […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy